JPWO2019169004A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019169004A5 JPWO2019169004A5 JP2020545159A JP2020545159A JPWO2019169004A5 JP WO2019169004 A5 JPWO2019169004 A5 JP WO2019169004A5 JP 2020545159 A JP2020545159 A JP 2020545159A JP 2020545159 A JP2020545159 A JP 2020545159A JP WO2019169004 A5 JPWO2019169004 A5 JP WO2019169004A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- protein
- capsid
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 96
- 235000018102 proteins Nutrition 0.000 claims 94
- 102000004169 proteins and genes Human genes 0.000 claims 94
- 150000001413 amino acids Chemical group 0.000 claims 93
- 241000702421 Dependoparvovirus Species 0.000 claims 48
- 150000007523 nucleic acids Chemical group 0.000 claims 47
- 210000000234 capsid Anatomy 0.000 claims 46
- 235000001014 amino acid Nutrition 0.000 claims 45
- 229940024606 amino acid Drugs 0.000 claims 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 32
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 24
- 108090000565 Capsid Proteins Proteins 0.000 claims 23
- 102100023321 Ceruloplasmin Human genes 0.000 claims 23
- 239000002773 nucleotide Substances 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 239000004471 Glycine Substances 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 13
- 230000004048 modification Effects 0.000 claims 11
- 238000012986 modification Methods 0.000 claims 11
- 230000006240 deamidation Effects 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 9
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 6
- 235000003704 aspartic acid Nutrition 0.000 claims 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 6
- 238000004949 mass spectrometry Methods 0.000 claims 6
- 239000013647 rAAV8 vector Substances 0.000 claims 6
- 235000009582 asparagine Nutrition 0.000 claims 5
- 239000004220 glutamic acid Substances 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 150000001508 asparagines Chemical class 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 3
- 101150066583 rep gene Proteins 0.000 claims 3
- 229960004799 tryptophan Drugs 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 238000013322 recombinant adeno-associated virus production system Methods 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 239000006035 Tryptophane Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
Applications Claiming Priority (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862635968P | 2018-02-27 | 2018-02-27 | |
US201862635964P | 2018-02-27 | 2018-02-27 | |
US62/635,964 | 2018-02-27 | ||
US62/635,968 | 2018-02-27 | ||
US201862663797P | 2018-04-27 | 2018-04-27 | |
US201862663788P | 2018-04-27 | 2018-04-27 | |
US62/663,788 | 2018-04-27 | ||
US62/663,797 | 2018-04-27 | ||
US201862667587P | 2018-05-06 | 2018-05-06 | |
US62/667,585 | 2018-05-06 | ||
US62/667,587 | 2018-05-06 | ||
US201862667888P | 2018-05-07 | 2018-05-07 | |
US201862667881P | 2018-05-07 | 2018-05-07 | |
US62/667,881 | 2018-05-07 | ||
US62/667,888 | 2018-05-07 | ||
US201862677471P | 2018-05-29 | 2018-05-29 | |
US201862667585P | 2018-05-29 | 2018-05-29 | |
US201862677474P | 2018-05-29 | 2018-05-29 | |
US62/677,471 | 2018-05-29 | ||
US62/677,474 | 2018-05-29 | ||
US201862703673P | 2018-07-26 | 2018-07-26 | |
US201862703670P | 2018-07-26 | 2018-07-26 | |
US62/703,673 | 2018-07-26 | ||
US62/703,670 | 2018-07-26 | ||
US201862722382P | 2018-08-24 | 2018-08-24 | |
US201862722388P | 2018-08-24 | 2018-08-24 | |
US62/722,382 | 2018-08-24 | ||
US62/722,388 | 2018-08-24 | ||
PCT/US2019/019861 WO2019169004A1 (en) | 2018-02-27 | 2019-02-27 | Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021515548A JP2021515548A (ja) | 2021-06-24 |
JPWO2019169004A5 true JPWO2019169004A5 (hr) | 2022-02-18 |
JP7498665B2 JP7498665B2 (ja) | 2024-06-12 |
Family
ID=67809202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020545159A Active JP7498665B2 (ja) | 2018-02-27 | 2019-02-27 | 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210123073A1 (hr) |
EP (1) | EP3768695A4 (hr) |
JP (1) | JP7498665B2 (hr) |
KR (1) | KR20210006327A (hr) |
CN (1) | CN112236443A (hr) |
AU (1) | AU2019228504A1 (hr) |
BR (1) | BR112020017278A2 (hr) |
CA (1) | CA3091795A1 (hr) |
CL (1) | CL2020002201A1 (hr) |
IL (1) | IL276860A (hr) |
MA (1) | MA52087A (hr) |
MX (1) | MX2020008932A (hr) |
SG (1) | SG11202007942YA (hr) |
WO (1) | WO2019169004A1 (hr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202107733QA (en) | 2015-09-28 | 2021-09-29 | Univ North Carolina Chapel Hill | Methods and compositions for antibody-evading virus vectors |
WO2019195449A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
EP3884057A4 (en) * | 2018-12-21 | 2022-09-07 | The University of North Carolina at Chapel Hill | OPTIMIZED GALC GENES AND EXPRESSION CASSETTE AND THEIR USE |
MX2021011468A (es) | 2019-03-21 | 2021-12-15 | Vectores de virus adenoasociados recombinantes. | |
WO2021076925A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
TW202130653A (zh) * | 2019-10-21 | 2021-08-16 | 賓州大學委員會 | 具改進生產產率及肝臟趨性之aav3b變異體 |
MX2022008003A (es) * | 2020-01-03 | 2022-10-07 | Sarepta Therapeutics Inc | Métodos para analizar proteínas de la cápside de aav. |
WO2021183433A1 (en) * | 2020-03-09 | 2021-09-16 | University Of Massachusetts | Gene replacement therapy for foxg1 syndrome |
WO2021257668A1 (en) | 2020-06-17 | 2021-12-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
IL299762A (en) | 2020-07-13 | 2023-03-01 | Univ Pennsylvania | Useful preparations for the treatment of Charcot-Marietot disease |
CA3195553A1 (en) * | 2020-10-18 | 2022-04-21 | Qiang Wang | Improved adeno-associated virus (aav) vector and uses therefor |
CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
JP2024515612A (ja) | 2021-04-12 | 2024-04-10 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 球脊髄性筋萎縮症(sbma)の治療に有用な組成物 |
WO2023081807A1 (en) * | 2021-11-04 | 2023-05-11 | The Trustees of the University of Pennsylvania Penn Center for Innovation | Compositions and methods for reducing pcsk9 levels in a subject |
WO2023133584A1 (en) | 2022-01-10 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
WO2023133574A1 (en) | 2022-01-10 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful for treatment of c9orf72-mediated disorders |
WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070172460A1 (en) * | 2003-03-19 | 2007-07-26 | Jurgen Kleinschmidt | Random peptide library displayed on aav vectors |
DK3211085T3 (da) * | 2003-09-30 | 2021-06-21 | Univ Pennsylvania | Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf |
DK2359867T3 (en) | 2005-04-07 | 2015-01-05 | Univ Pennsylvania | A method for increasing an AAV vector function |
WO2016049230A1 (en) * | 2014-09-24 | 2016-03-31 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
EP3224362A4 (en) * | 2014-11-26 | 2018-06-06 | The Regents of The University of California | Therapeutic compositions comprising transcription factors and methods of making and using the same |
IL298604A (en) * | 2016-04-15 | 2023-01-01 | Univ Pennsylvania | Novel aav8 mutant capsids and preparations containing them |
MX2019000962A (es) * | 2016-07-26 | 2019-08-01 | Biomarin Pharm Inc | Novedosas proteinas de la capside del virus adenoasociado. |
TN2019000047A1 (en) * | 2016-08-15 | 2020-07-15 | Genzyme Corp | Methods for detecting aav |
HRP20240257T1 (hr) * | 2017-02-28 | 2024-05-24 | The Trustees Of The University Of Pennsylvania | Adeno-povezani virusni (aav) clade f vektor i njegova uporaba |
JOP20190200A1 (ar) * | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
-
2019
- 2019-02-27 BR BR112020017278-2A patent/BR112020017278A2/pt unknown
- 2019-02-27 CA CA3091795A patent/CA3091795A1/en active Pending
- 2019-02-27 MA MA052087A patent/MA52087A/fr unknown
- 2019-02-27 KR KR1020207027462A patent/KR20210006327A/ko active Search and Examination
- 2019-02-27 AU AU2019228504A patent/AU2019228504A1/en active Pending
- 2019-02-27 MX MX2020008932A patent/MX2020008932A/es unknown
- 2019-02-27 US US16/975,545 patent/US20210123073A1/en active Pending
- 2019-02-27 CN CN201980029022.1A patent/CN112236443A/zh active Pending
- 2019-02-27 WO PCT/US2019/019861 patent/WO2019169004A1/en unknown
- 2019-02-27 JP JP2020545159A patent/JP7498665B2/ja active Active
- 2019-02-27 SG SG11202007942YA patent/SG11202007942YA/en unknown
- 2019-02-27 EP EP19760152.9A patent/EP3768695A4/en active Pending
-
2020
- 2020-08-23 IL IL276860A patent/IL276860A/en unknown
- 2020-08-26 CL CL2020002201A patent/CL2020002201A1/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020510429A5 (hr) | ||
JPWO2019169004A5 (hr) | ||
CN109563496B (zh) | 用于重组蛋白和/或病毒载体生产的细胞系 | |
JP5268890B2 (ja) | Aavの規模適応性の製造方法 | |
FI3589730T3 (fi) | Kladin f adenoassosioitunut virus (aav) -vektori ja sen käyttötapoja | |
US6593123B1 (en) | Large-scale recombinant adeno-associated virus (rAAV) production and purification | |
US7220577B2 (en) | Modified AAV | |
JP2018108113A5 (hr) | ||
JPWO2019168961A5 (hr) | ||
IL259595B2 (en) | Gradual methods for the production of a recombinant adenovirus (AAV) vector in a serum-free suspension cell culture system suitable for clinical use | |
CN110997912A (zh) | 用于改进的细胞转染和/或rAAV载体生产的增强剂 | |
US11905524B2 (en) | AAV chimeras | |
AU2003272672B2 (en) | High titer recombinant AAV production | |
US20220186255A1 (en) | Methods for the manufacture of recombinant viral vectors | |
JPWO2020223232A5 (hr) | ||
JP2023518919A (ja) | Aavを産生する方法 | |
JPWO2020223236A5 (hr) | ||
JPWO2020223231A5 (hr) | ||
JP7481755B2 (ja) | 組換えパルボウイルスベクターならびにその作製および使用方法 | |
JP2024514956A (ja) | 組織標的化された改変aavカプシドおよびその使用方法 | |
AR123838A1 (es) | Vector mejorado de virus adenoasociado (aav) y usos de este | |
JP2023529855A (ja) | Smn1タンパク質をコードするコドン最適化した核酸およびその使用 | |
US20240084268A1 (en) | Method for purifying recombinant viral particles | |
CN116063404A (zh) | 可提高AAV包装能力的衣壳蛋白MutD及其应用 | |
RU2820088C1 (ru) | Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе |